Validation checklist for initial marketing authorisation applications - biologicals other than immunologicals (applicable to submissions under Regulation (EU) 2019/6)

June 20, 2022

3D rendering of a checkmark in a checkbox.

JUNE 2022

EMA/278419/2022-Rev.1

This validation checklist is used by the Agency to validate initial marketing authorization applications for pharmaceuticals and applicants should use it as a means to review in advance of their submission that standard requirements are fulfilled.

Download the Checklist

Interested in learning more? Contact us today to find out how we can help not only with your EMA/FDA submissions, but all of your global regulatory needs.

TAGS:

April 26, 2022

EMA and the EUnetHTA 21 consortium set priorities for their collaboration Share

April 12, 2022 The European Medicines Agency (EMA) and the European Network for Health Technology Assessment (EUnetHTA) 21 consortium have published a PDF icon joint work plan until 2023. The focus...

Several COVID-19 vaccine vials lined up on a table.

June 24, 2022

EMA Procedural guidance for variant strain(s) update to vaccines intended for protection against Human coronavirus

8 June 2022 EMA/175959/2021 Rev.2 Human Medicines Division Regulatory and procedural requirements Introduction In order to ensure the continued effectiveness of authorised COVID-19 vaccines, it may...

EMA flags in front of buildings.

June 23, 2022

EMA Checklist for annual updates for parallel distribution - Draft Guidance

22/06/2022 EMA/405782/2020 Rev. 3 Human Medicines Division The European Medicines Agency (hereinafter 'the Agency') asks its applicants to use this checklist in advance of submission of an annual...